Personalized mRNA Cancer Vaccine Holds Up Through Five Years of Follow-Up, With the Post-Surgery Melanoma Recurrence Gap Persisting

Complete removal of melanoma does not mean the threat is over. For patients at higher risk of recurrence, the real challenge is how to eliminate residual cancer cells that cannot be seen on imaging. Intismeran autogene, a personalized mRNA therapy jointly developed by Moderna and Merck, has now maintained its early efficacy signal through five years of follow-up, providing longer-term clinical evidence for the approach of “making a separate vaccine based on each patient’s tumor.”

KEYNOTE-942 is a randomized, open-label phase 2 trial that enrolled 157 patients with completely resected, high-risk stage III or IV melanoma. Of these, 107 received intismeran with the anti-PD-1 drug pembrolizumab, while another 50 received pembrolizumab alone. After a median follow-up of 60.3 months, the five-year recurrence-free survival rate was 68.8% in the combination group and 49.1% in the control group; the hazard ratio for recurrence or death was 0.51, equivalent to a 49% reduction in relative risk.

A difference also emerged for more difficult-to-treat distant metastases: the combination treatment reduced the relative risk of distant metastasis or death by 59%, with a hazard ratio of 0.411. However, these figures describe the relative difference in the rate at which events occurred between the two groups and cannot be interpreted as meaning that every patient’s probability of recurrence was cut in half. Although the overall survival analysis favored the combination treatment, only 14 deaths occurred in the trial, and the confidence interval was wide, so a life-extension benefit has not yet been demonstrated.

This therapy is not a general-purpose vaccine for preventing infection. Researchers first sequence a patient’s tumor and select up to 34 “neoantigens” that may exist only in cancer cells, then create a personalized mRNA formulation intended to teach T cells to recognize residual tumors. Patients received 1 milligram of intismeran every three weeks for a total of nine doses, together with up to 18 doses of pembrolizumab; the former provides recognition targets, while the latter releases the brake that cancer cells place on the immune response.

No new major safety signals emerged. Common adverse effects associated with intismeran included fatigue, injection-site pain, and chills, and no grade 4 or 5 adverse events attributed to the therapy were reported. Immune-related adverse events occurred in 45.2% of the combination group and 44% of the monotherapy group, indicating that adding the vaccine did not clearly increase the overall proportion of such events; however, the sample size remains insufficient to rule out rare risks.

Background

The personalized approach differs from mRNA therapies that use fixed tumor antigens: it may more closely match the mutational profile of each tumor, but at the cost of requiring sequencing, design, and production for each individual, with implications for manufacturing speed, cost, and access to care. Moderna and Merck have advanced intismeran into a phase 3 melanoma trial and have begun studies in cancers including lung cancer, bladder cancer, and renal cell carcinoma; its clinical role will ultimately be determined by whether larger trials can reproduce the effect and confirm an overall survival benefit.

These data also come at a time when mRNA technology is highly politicized. Conflating personalized cancer treatments with vaccines that prevent infectious diseases can easily obscure the differences between them in purpose, manufacturing, and evidentiary thresholds; conversely, the technology’s aura cannot replace rigorous validation. Five years of follow-up makes the efficacy signal more credible, but it is not yet the endpoint for approval, widespread adoption, or rewriting the standard of care.